- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07675811
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs".
The aim of the study is to see what side effects freneslerbart, mevonlerbart, and REGN-2Cat may have and if they help reduce eye allergy symptoms caused by cat hair/dander compared with a placebo.
The study is looking at several other research questions, including:
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
- How long the study drug effect lasts
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-post: clinicaltrials@regeneron.com
Studieorter
-
-
California
-
Long Beach, California, Förenta staterna, 90815
- Rekrytering
- Ark Clinical Research, LLC
-
-
Massachusetts
-
Andover, Massachusetts, Förenta staterna, 01810
- Rekrytering
- Andover Eye Associates
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Part A: adult participants aged 18 years and older. For part B: pediatric participants ≥8 years and <18 years, and adult participants aged 18 years and older.
- Positive SPT to cat allergen extract
- Positive specific Immunoglobulin E (sIgE) tests for cat and Fel d 1
- Positive CAC criteria
Key Exclusion Criteria:
- Significant and/or severe environmental allergies causing symptoms (eg, ocular itching, ocular redness, etc) outside of the challenge setting that are expected to coincide or may interfere with study assessments
- Presence of any ophthalmic disease/ abnormality/ condition that may interfere with study assessments, affect the study outcomes or participant safety
- A clinical history of asthma with treatment of asthma requiring systemic (oral or parenteral) corticosteroid treatment as defined in the protocol
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: REGN-2Cat
Part A and B |
Administered per the protocol
Andra namn:
|
|
Experimentell: Freneslerbart
Part A and B |
Administered per the protocol
Andra namn:
|
|
Experimentell: Mevonlerbart
Part A |
Administered per the protocol
Andra namn:
|
|
Placebo-jämförare: Matching placebo
Part A and B |
Administered per the protocol |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Ocular itch score in participants receiving REGN-2Cat as compared to placebo
Tidsram: At day 8, post-Conjunctival Allergen Challenge (CAC)
|
At day 8, post-Conjunctival Allergen Challenge (CAC)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
1. Ocular itch score in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
2. Conjunctival redness score in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
3. Achievement of at least a 1-point reduction from baseline in ocular itch score for at least 2 out of 3 post-CAC time points in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
4. Achievement of at least a 1-point reduction from baseline in conjunctival redness score for at least 2 out of 3 post-CAC time points in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
5. Percent change from baseline in cat titrated Skin Prick Test (tSPT) in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85
|
Up to day 85
|
|
|
6. Ocular itch score in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
7. Conjunctival redness score in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
8. Achievement of at least a 1-point reduction from baseline in ocular itch score for at least 2 out of 3 post-CAC time points in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
9. Achievement of at least a 1-point reduction from baseline in conjunctival redness score for at least 2 out of 3 post-CAC time points in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
10. Percent change from baseline in cat tSPT in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85
|
Up to day 85
|
|
|
16. Ocular itch score in participants receiving REGN-2Cat as compared to freneslerbart
Tidsram: At day 8, post-CAC
|
At day 8, post-CAC
|
|
|
17. Achievements of different degrees of clinical response, as measured by change from baseline in ocular itch score among participants receiving REGN-2Cat, freneslerbart, mevonlerbart or placebo
Tidsram: At day 8, post-CAC
|
At day 8, post-CAC
|
|
|
18. Percent change from baseline in cat tSPT in participants receiving REGN-2Cat as compared to freneslerbart
Tidsram: At day 8
|
At day 8
|
|
|
20. Ciliary redness score in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
21. Episcleral redness score in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
22. Total redness score in participants receiving REGN-2Cat as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
23. Ciliary redness score in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
24. Episcleral redness score in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
25. Total redness score in participants receiving freneslerbart as compared to placebo
Tidsram: Up to day 85, post-CAC
|
Up to day 85, post-CAC
|
|
|
27. Occurrence of Treatment Emergent Adverse Events (TEAEs)
Tidsram: Up to day 113
|
Up to day 113
|
|
|
28. Severity of TEAEs
Tidsram: Up to day 113
|
Up to day 113
|
|
|
29. Occurrence of Treatment Emergent-Serious Adverse Events (TE-SAEs)
Tidsram: Up to day 113
|
Up to day 113
|
|
|
30. Concentrations of total freneslerbart in serum
Tidsram: Up to day 113
|
Up to day 113
|
|
|
31. Concentrations of total mevonlerbart in serum
Tidsram: Up to day 113
|
Up to day 113
|
|
|
32. Occurrence of Anti-Drug Antibodies (ADA) to freneslerbart
Tidsram: Up to day 113
|
Up to day 113
|
|
|
33. Magnitude of ADA to freneslerbart
Tidsram: Up to day 113
|
Up to day 113
|
|
|
34. Occurrence of ADA to mevonlerbart
Tidsram: Up to day 113
|
Up to day 113
|
|
|
35. Magnitude of ADA to mevonlerbart
Tidsram: Up to day 113
|
Up to day 113
|
|
|
11. Ocular itch score in participants receiving mevonlerbart as compared to placebo
Tidsram: At day 8, post-CAC
|
Part A |
At day 8, post-CAC
|
|
12. Conjunctival redness score in participants receiving mevonlerbart as compared to placebo
Tidsram: At day 8, post-CAC
|
Part A |
At day 8, post-CAC
|
|
13. Achievement of at least a 1-point reduction from baseline in ocular itch score for at least 2 out of 3 post-CAC time points in participants receiving mevonlerbart as compared to placebo
Tidsram: At day 8, post-CAC
|
Part A |
At day 8, post-CAC
|
|
14. Achievement of at least a 1-point reduction from baseline in conjunctival redness score for at least 2 out of 3 post-CAC time points in participants receiving mevonlerbart as compared to placebo
Tidsram: At day 8, post-CAC
|
Part A |
At day 8, post-CAC
|
|
15. Ocular itch score in participants receiving REGN-2Cat as compared to mevonlerbart
Tidsram: At day 8, post-CAC
|
Part A |
At day 8, post-CAC
|
|
19. Percent change from baseline in cat tSPT in participants receiving REGN-2Cat as compared to mevonlerbart
Tidsram: At day 8
|
Part A |
At day 8
|
|
26. Percent change from baseline in cat tSPT in participants receiving mevonlerbart as compared to placebo
Tidsram: Up to day 85
|
Part A |
Up to day 85
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trial Management, Regeneron Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- R1908-1909-ALG-2582
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Tidsram för IPD-delning
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Kriterier för IPD Sharing Access
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .